With seeds from Turning Point, a new biotech blooms with $100M to take on small molecules

The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D. | The first signs of spring are beginning to emerge and so too are the shoots of the next biotech from drug designer J. Jean Cui, Ph.D. BlossomHill Therapeutics has raised $100 million in a series B financing, bringing the company’s total fundraising to $173 million so far.